For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Access a highly defined, scalable, and consistent source of human cells at Abcam. We are introducing human-induced pluripotent stem cell (hiPSC) derived human cell types generated by opti-ox1 cellular reprogramming through our partnership with bit.bio, providing you with high-quality human models for research, drug development, and high-throughput screening.
The advent of stem cell technologies has opened up new opportunities in drug discovery and development by providing new tools for drug screening, target identification, and toxicity testing. The discovery of reprogramming patient-derived somatic cells into iPSCs has offered a promising alternative to generate many human cell types but rarely at the scale, consistency, and cost point required for HTS.
The widespread use of hiPSC-derived, mature cell types has been restricted by complex and suboptimal differentiation protocols. By applying a cellular reprogramming approach supported by a uniquely engineered genetic switch, opti-ox (optimized inducible overexpression) technology, these restrictions have been largely overcome.
This proprietary technology overcomes gene silencing and enables controlled expression of transcription factors, resulting in deterministic reprogramming of hiPSC cultures. opti-ox technology can generate cells with high consistency and functionality at scale from hiPSCs, including those carrying disease-specific mutations, providing high-quality human models for enhanced research outcomes and drug discovery efficiency.
opti-ox cellular reprogramming offers access to the highest quality cellular models with simple protocols. Homogenous, mature hiPSC- derived functional cells can be manufactured within days, significantly reducing the time and resources it takes to generate mature cell types.
Consistency: Batch-to-batch reproducibility and homogeneity create a stable human model for research and high throughput.
Speed: Ready for experimentation within days post revival.
Scalability: Industrial scale quantities allow the cells to be used in a range of applications, from research to screening purposes.
Ease of Use: Cells arrive programmed to rapidly mature upon revival with only one medium required in a two-step protocol.
Our range is constantly expanding, and we will be introducing additional cell types soon.